Marked advancements are being made in the treatment of early-stage breast cancer, but many women still develop recurrence and metastasis. In addition, 5–10% of breast cancer patients have metastatic disease at presentation. While treatments for metastatic breast cancer continue to improve, there remains no cure once distant metastases develop, and over 40,000 women die of advanced disease annually in the United States alone. Balancing therapeutic efficacy in relation to side effects is critical. This chapter provides an overview of systemic therapy options for patients with metastatic breast cancer.
Breast Cancer Estrogen Receptor Metastatic Breast Cancer Vinca Alkaloid Initial Chemotherapy
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Knight WA et al. Hormone receptors in primary and advanced breast cancer. Clin Endocrin Metab. 1980;9:361–8.CrossRefGoogle Scholar
Bonneterre J et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol. 2000;22:3748–57.Google Scholar
Mouridsen H et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausalwomen: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003;21:2101–9.PubMedCrossRefGoogle Scholar
O’Shaughnessy J et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20(12):2812–23.PubMedCrossRefGoogle Scholar
Seidman AD. Gemcitabine and docetaxel in metastatic breast cancer. Oncology (Williston Park). 2004;14(supp 12):13–6.Google Scholar
Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(2010):783–92.PubMedCrossRefGoogle Scholar
Hortobagyi GN et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996;335(24):1785–91.PubMedCrossRefGoogle Scholar
Hortobagyi GN et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol. 1998; 16(6):2038–44.PubMedGoogle Scholar